Hong Kong becomes a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Regulatory Authorities, taking a key step toward building an international hub for medical innovation.

date
15:31 20/11/2026
avatar
GMT Eight
Hong Kong has officially become a member of the ICH, representing international recognition of its drug research and development and regulatory standards. This will help further advance the development of the capabilities and mechanisms for "first-tier approval" of innovative drugs, enable deep participation in formulating international rules for drug development and registration, and accelerate the building of an international hub for medical innovation.
On November 20, the Hong Kong Health Bureau announced that Hong Kong, China has officially joined the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) as a regulatory authority member. The ICH is an important international platform for harmonising technical standards for drug regulation. Hong Kong's official membership in the ICH represents international recognition of its drug research and development and regulatory standards, helps further advance the development of its "first-tier approval" capabilities and mechanisms for innovative drugs, enables its deep participation in formulating international rules for drug development and registration, and accelerates the building of an international hub for medical innovation. At the ICH assembly held in the Czech Republic on November 17, 2026, Hong Kong, China (represented by the Pharmacy and Poisons Board of Hong Kong) was approved as its 20th regulatory authority member. Other ICH regulatory authority members include the National Medical Products Administration of China, as well as regulators from Europe, Switzerland, the United Kingdom and the United States. Professor Lo Chung-mau, Secretary for Health of Hong Kong, said: "The SAR Government sincerely thanks the country for its unwavering full support for Hong Kong's development into an international hub for medical innovation. Hong Kong, China's becoming an ICH regulatory authority member fully demonstrates the unique advantages of 'one country, two systems.' Since becoming an ICH observer on October 31, 2023, Hong Kong has, with the country's strong support, made every effort to meet all ICH requirements, enabling it to become a full ICH regulatory authority member in just three yearsa process greatly accelerated compared with the eight to ten years estimated by the Government earlier based on international experience." Professor Lo Chung-mau added: "Looking ahead, the SAR Government will, in accordance with the First Five-Year Plan for Economic and Social Development of the Hong Kong Special Administrative Region (20262030), actively align with the national 15th Five-Year Plan, support clinical research and development in biomedicine, and optimise the review and approval of innovative drugs and clinically urgently needed drugs. The SAR Government will next month establish the Centre for Medical Products Regulation (CMPR) to build independent drug review and approval capabilities, actively participate in international cooperation, build Hong Kong into an international hub for medical innovation, and better integrate into and serve the overall national development." Dr Lam Man-kin, Director of Health of Hong Kong, said: "Joining the ICH is an important milestone in Hong Kong's drug review, approval and regulatory reform, and is especially important for the soon-to-be-established CMPR. The CMPR will, in accordance with ICH technical requirements, build a professional team for independent review and approval, enhance the efficiency of reviewing innovative drugs, and send experts to participate in the formulation and revision of ICH guidelines, contributing to the scientific advancement of global drug regulation. Hong Kong is now both an ICH regulatory authority member and a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). The CMPR will be science-based and strive to become an internationally authoritative regulatory authority." The ICH is an authoritative international pharmaceutical harmonisation body whose purpose is to harmonise global technical requirements for drug registration, formulate international guideline principles of the highest standards covering safety, efficacy and quality, and safeguard public health. The PIC/S is an authoritative international organisation composed of drug regulatory authorities from multiple countries and regions, whose mission is to lead international development in medicinal products, formulate and implement rigorous Good Manufacturing Practice guidelines and a quality management system for drug inspections. Hong Kong, China passed its assessment in 2015 and officially became a PIC/S member on January 1, 2016.